About CovEpiAb
CovEpiAb is a comprehensive database and analysis resource of human coronavirus (HCoVs) immune epitopes and antibodies. CovEpiAb contains information on over 60,000 experimentally validated epitopes and over 12,000 antibodies for HCoVs and SARS-CoV-2 variants. The database is unique in:
(1) classifying and annotating cross-reactive epitopes from different viruses and variants,
(2) providing molecular and experimental interaction profiles of antibodies, including structure-based binding sites and around 70,000 data on binding affinity and neutralizing activity,
(3) providing virological characteristics of current and past circulating SARS-CoV-2 variants and in vitro activity of various therapeutics,
(4) offering site-level annotations of key functional features, including immune epitope, antibody binding, SARS-CoV-2 mutations, receptor binding, mAb resistance and conservation.
(5) offering an integrated online pipeline for B-cell and T-cell epitope prediction, named COVEP.
Overall, CovEpiAb provides an important resource for SARS-CoV-2-related research and facilitates the development of broad-spectrum effective vaccines and neutralizing antibodies against HCoVs.
About COVEP
Integrated epitope prediction tools
COVEP is an integration of existing recognized epitope prediction tools and provides a user-friendly application and web interface.
NetMHCpan4.0, MHCflurry2.0, and DeepHLApan were employed for MHC class I T-cell epitope prediction, and MixMHC2pred and NetMHCIIpan were utilized for MHC class II epitope prediction. These tools have been validated for their accuracy in the literature and are widely used by researchers.
Seven IEDB built-in tools were used for B-cell epitope prediction, including BepiPred, BepiPred-2.0, Chou, and Fasman beta turn prediction, Emini surface accessibility scale, Karplus and Schulz flexibility scale, Kolaskar and Tongaonkar antigenicity scale, and Parker hydrophilicity prediction. They are also commonly used and recognized tools. The prediction accuracy of these tools has been validated and compared in their own papers. Users can see their papers for details.
✝ The prediction accuracy of these tools has been validated and compared in their own papers.
* Citations as of February 1, 2024.
Usage of COVEP
COVEP offers a comprehensive set of resources for users:
1. Online Web Server: Access COVEP's functionality through a user-friendly web interface. Please refer to the tutorial for details on how to use COVEP's webserver.
2. Docker Image: Obtain the Docker image for seamless deployment and usage.
3. Source Code: Explore and download the source code directly from the project's GitHub repository. See the README file for more detailed information.
Downloads
Validated B- and T-cell epitopes against HCoVs | |||||||||
---|---|---|---|---|---|---|---|---|---|
Experimental Validated B cell epitopes against HCoVs and their biological context. | Click to save | ||||||||
Experimental Validated T cell epitopes against HCoVs and their biological context. | Click to save | ||||||||
Bind and Neutralizing antibodies against HCoVs | |||||||||
Experimental Validated antibodies against HCoVs and their biological context. | Click to save | ||||||||
SARS-CoV-2 variants and therapeutic data | |||||||||
SARS-CoV-2 variants | Click to save | ||||||||
Virological features of SARS-CoV-2 variants | Click to save | ||||||||
Advanced therapeutic data | Click to save | ||||||||
Predicted epitopes for HCoVs | |||||||||
Predicted B cell epitopes against HCoVs. | Click to save | ||||||||
Predicted CD8+ T cell epitopes against HCoVs. | Click to save | ||||||||
Predicted CD4+ T cell epitopes against HCoVs. | Click to save | ||||||||
Conservation and consensus squence of HCoVs homologous protein | |||||||||
Site conservation of HCoVs homologous protein. | Click to save | ||||||||
Consensus sequence of HCoVs homologous protein. | Click to save |
Cite Us
Zhang X, Wu J, Luo Y, et al. CovEpiAb: a comprehensive database and analysis resource for immune epitopes and antibodies of human coronaviruses. Brief Bioinform. 2024;25(3):bbae183. https://doi.org/10.1093/bib/bbae183
Contact Us
Dr. Zhan Zhou, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China 310058 zhanzhou@zju.edu.cn